Insider · CIK 0001331852

Zakrzewski Joseph S

Reports to the SEC for 8 companies · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001331852

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-14	ANTXAN2 Therapeutics, Inc.G Gift	Director	GGift	−406K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+100K sh	—	—	99,999
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−100K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.4K sh	—	—	10,362
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.4K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.7K sh	—	—	23,742
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−23.7K sh	—	—	0
2026-02-20	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.4K sh	—	—	20,400
2025-05-22	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+19.1K sh	—	—	19,111
2025-04-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+10.5K sh	—	—	145,538
2024-12-19	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+9,816 sh	—	—	135,015
2024-11-27	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+2,000 sh	$1.40	+$2,800	125,199
2024-11-19	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+5,000 sh	$1.01	+$5,050	123,199
2024-11-18	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+20K sh	$1.00	+$20K	118,199
2024-06-19	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+64.5K sh	—	—	64,503
2024-02-06	Cyteir Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+14.2K sh	$1.69	+$23.9K	227,439
2024-02-06	Cyteir Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−14.2K sh	—	—	0
2024-01-18	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−100K sh	$19.11	−$1.91M	405,880
2023-06-07	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.7K sh	—	—	23,742
2023-02-03	Cyteir Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+14.2K sh	—	—	14,150
2022-12-07	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+21.2K sh	$1.30	+$27.6K	154,618
2022-05-12	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.4K sh	—	—	10,362
2022-05-12	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+743 sh	$1.61	+$1,196.23	133,416
2022-05-11	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+1,000 sh	$1.70	+$1,700	132,673
2022-05-10	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+49.4K sh	$1.89	+$93.4K	131,673
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director	CConversion	+98.2K sh	—	—	98,199
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	Director	CConversion	−98.2K sh	—	—	0
2022-02-25	SGMOQSANGAMO THERAPEUTICS, INCA Award	Director	AAward	+12.5K sh	—	—	60,700
2022-02-25	SGMOQSANGAMO THERAPEUTICS, INC · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2022-02-22	Cyteir Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+14.2K sh	—	—	14,150
2021-12-28	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+601 sh	$9.85	+$5,919.85	82,267
2021-12-27	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+200 sh	$9.97	+$1,994	81,567
2021-12-27	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+99 sh	$10.18	+$1,007.82	81,666
2021-12-23	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+200 sh	$9.87	+$1,974	81,367
2021-12-17	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+200 sh	$9.88	+$1,976	81,167
2021-12-15	AMRNAMARIN CORP PLC\UKP Purchase	Director	PPurchase	+2,000 sh	$3.15	+$6,310	196,547
2021-12-15	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+2,000 sh	$10.47	+$20.9K	79,267
2021-12-15	Cyteir Therapeutics, Inc.P Purchase	Director	PPurchase	+1,700 sh	$11.12	+$18.9K	80,967
2021-12-14	AMRNAMARIN CORP PLC\UKP Purchase	Director	PPurchase	+10K sh	$3.27	+$32.7K	194,547
2021-11-19	ACCELERON PHARMA INCU Disposition from Tender	Director	UDisposition from Tender	−34.5K sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	Director	DDisposition to Issuer	−10K sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	Director	DDisposition to Issuer	−7,500 sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	Director	DDisposition to Issuer	−7,500 sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	Director	DDisposition to Issuer	−10K sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	Director	DDisposition to Issuer	−7,500 sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	Director	DDisposition to Issuer	−8,185 sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	Director	DDisposition to Issuer	−3,222 sh	—	—	0
2021-06-22	Cyteir Therapeutics, Inc.C Conversion	Director	CConversion	+58.7K sh	—	—	58,671
2021-06-22	Cyteir Therapeutics, Inc.Series B Convertible Preferred StockC Conversion	Director	CConversion	−200K sh	—	—	0
2021-06-14	AMRNAMARIN CORP PLC\UK · Stock Option (Right to Buy)A Award	Director	AAward	+46K sh	—	—	45,953

Recent filings

Accepted (ET)
Aug 144
Zakrzewski Joseph S0001193125-26-351801
SEC(opens sec.gov)
Mar 234
Zakrzewski Joseph S0001193125-26-120214
SEC(opens sec.gov)
Feb 234
Zakrzewski Joseph S0001193125-26-063984
SEC(opens sec.gov)
May 234
Zakrzewski Joseph S0000950170-25-077061
SEC(opens sec.gov)
Apr 114
Zakrzewski Joseph S0000950170-25-053373
SEC(opens sec.gov)
Dec 234
Zakrzewski Joseph S0000950170-24-139793
SEC(opens sec.gov)
Nov 274
Zakrzewski Joseph S0000950170-24-131499
SEC(opens sec.gov)
Nov 204
Zakrzewski Joseph S0000950170-24-129248
SEC(opens sec.gov)
Jun 214
Zakrzewski Joseph S0000950170-24-076399
SEC(opens sec.gov)
Feb 84
Zakrzewski Joseph S0001209191-24-002992
SEC(opens sec.gov)
Jan 194
Zakrzewski Joseph S0000950170-24-005900
SEC(opens sec.gov)
Jun 94
Zakrzewski Joseph S0000899243-23-015321
SEC(opens sec.gov)
Feb 74
Zakrzewski Joseph S0001209191-23-007560
SEC(opens sec.gov)

Companies

Address

C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100

MENLO PARK, CA, 94025